Recent clinical studies showed that SGLT2 inhibitor class of anti-diabetic medications had positive cardiovascular effects, including a decrease in cardiovascular death, non-fatal myocardial infarction (MI), heart failure, and non-fatal stroke, as well as all-cause mortality [6]. This evidence concerns the gene SLC5A2 and heart failure.